Seeking Alpha

VRUS
Pharmasset, Inc.

5/26/2012, 12:38 PM ET
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
VRUS Market Currents more »
  • January 27 Idenix Pharmaceuticals (IDIX) -9.6% after Stifel Nicolaus downgrades shares to Sell from Hold at Stifel Nicolaus, which believes the "significant difference" in potency existing between IDIX's hepatitis C drug and those made by Pharmasset (VRUS) and Inhibitex (INHX) has important implications on how remaining "potential consolidators" strategically view the companies.
    Comment!
    [Healthcare, On the Move]
VRUS in Focus more »
VRUS Press Releases and Filings more »
VRUS Instablog posts more »
  • Prem Watsa - Fairfax Financial Holdings Q4/2011 Fund Portfolio
    Sat, Feb 25 • Dividend Sheet • Comment!
  • The Hepatitis C Gold Rush - Looking For The Right Fit For Idenix's Drug IDX184
    Tue, Feb 14 • EXPstocktrader • 1 Comment
  • ValuEngine Rates Medical Stocks
    Fri, Dec 16, 2011 • Steve Hach • Comment!
  • Biotech investment down – balance of power will return
    Mon, Nov 28, 2011 • Thanos Maroglou • Comment!
  • Hepatitis C Virus (HCV) Biotech/Pharma Stocks: (OTC: AEMD), (Nasdaq:VRUS), (VRTX)
    Fri, Nov 25, 2011 • Investorideas.com • Comment!
Write a post on VRUS
VRUS StockTalks
VRUS vs. ETF Alternatives
Company Description
Currently, there's no company description for VRUS.